SCRI Tennessee Oncology Nashville — Nashville, Tennessee

SCRI Tennessee Oncology Nashville is a clinical research site located in Nashville, Tennessee, United States 37203.

Crixeo Health Trust Score: 73/100 (FAIR). This profile has not yet been claimed by the site owner.

SCRI Tennessee Oncology Nashville has participated in 6 clinical trials.

Therapeutic areas: Follicular Lymphoma, Multiple Myeloma, Unresectable Locally Advanced or Metastatic Cancer.

Sponsors: Pharmacyclics LLC., Takeda, Nektar Therapeutics.

Sponsor Feasibility Report

Trust Score: 73/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for SCRI Tennessee Oncology Nashville?

SCRI Tennessee Oncology Nashville has a Crixeo Trust Score of 73/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has SCRI Tennessee Oncology Nashville conducted?

SCRI Tennessee Oncology Nashville has 6 clinical trials on record. Their work covers Follicular Lymphoma, Multiple Myeloma, Unresectable Locally Advanced or Metastatic Cancer.

Is SCRI Tennessee Oncology Nashville accredited by Crixeo Health?

Yes — SCRI Tennessee Oncology Nashville holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about SCRI Tennessee Oncology Nashville?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.